ClinicaliQ Trial Snapshot
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus — Recruiting • Phase III • Diabetes / Metabolic • NCT07662109.
- What is being tested: The study investigates a dual-agent combination therapy of elecoglipron (a GLP-1 receptor agonist) plus dapagliflozin (an SGLT2 inhibitor) versus each drug used alone, assessing efficacy, safety, and tolerability in adults with inadequately controlled type 2 diabetes on lifestyle….
- Patient eligibility overview: Adults with type 2 diabetes mellitus whose blood glucose remains inadequately controlled despite lifestyle management alone are eligible for inclusion in this Phase III trial.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Eligibility Snapshot
- : * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.